Dianthus Therapeutics (DNTH) Stock Price, News & Analysis

Company Overview

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted antibody therapies for autoimmune diseases. The company’s approach centers on selectively modulating the complement system, an immune pathway involved in inflammation and tissue damage, with the goal of creating treatments that may offer potent disease control and convenient dosing.

Dianthus’ lead investigational product is DNTH103, a fully human monoclonal antibody designed to selectively inhibit activated C1s, a key protein in the classical complement pathway. DNTH103 is engineered for extended activity and subcutaneous administration and is being evaluated in immune-mediated neuromuscular and neurological disorders, including generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. The company is also advancing additional complement-targeted programs for autoimmune diseases.

Dianthus serves global markets through its clinical development activities and is headquartered in the United States. As a development-stage biotechnology company, its products remain investigational and are subject to clinical testing and regulatory review before they may become commercially available.

Key Stats

• Today's Range: $87.73 to $91.24
• 50-Day Range: $87.16 to $115.96
• 52-Week Range: $32.22 to $117.88
• Volume: 751,384 shs
• Average Volume: 884,457 shs
• Market Capitalization: $4.83 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $129.83
• Consensus Rating: Moderate Buy

Dianthus Therapeutics Stock Analysis - MarketRank™

Dianthus Therapeutics scored higher than 34% of companies evaluated by MarketBeat, and ranked 702nd out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Dianthus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 1 strong buy rating, 13 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Dianthus Therapeutics has a consensus price target of $129.83, representing about 47.2% upside from its current price of $88.21.

Amount of Analyst Coverage

Dianthus Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Dianthus Therapeutics are expected to decrease in the coming year, from ($3.81) to ($4.74) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Dianthus Therapeutics is -21.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dianthus Therapeutics is -21.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Dianthus Therapeutics has a P/B Ratio of 7.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.61% of the float of Dianthus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Dianthus Therapeutics has a short interest ratio ("days to cover") of 14.42, which indicates bearish sentiment.

Change versus previous month

Short interest in Dianthus Therapeutics has recently increased by 4.74%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Dianthus Therapeutics does not currently pay a dividend.

Dividend Growth

Dianthus Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Dianthus Therapeutics this week, compared to 5 articles on an average week.

Search Interest

Only 2 people have searched for DNTH on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Dianthus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $29,276,000.00 in company stock.

Percentage Held by Insiders

3.02% of the stock of Dianthus Therapeutics is held by insiders.

Percentage Held by Institutions

47.53% of the stock of Dianthus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 10/02/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:DNTH
• CIK: 1690585
• Web: dianthustx.com
• Phone: (929) 999-4055
• Fax: N/A
• Employees: 92
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Dianthus Therapeutics: $129.83
• High Price Target: $158.00
• Low Price Target: $98.00
• Potential Upside/Downside: +47.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.93
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$162.34 million
• Net Margins: -10,096.95%
• Pretax Margin: -10,096.95%
• Return on Equity: -22.53%
• Return on Assets: -21.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 26.10
• Quick Ratio: 26.10

Sales & Book Value

• Annual Sales: $2.04 million
• Price / Sales: 2,369.56
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.41 per share
• Price / Book: 7.73

Miscellaneous

• Outstanding Shares: 54,800,000
• Free Float: 53,143,000
• Market Cap: $4.83 billion
• Optionable: Optionable
• Beta: 1.35